PEREGRINE PHARMACEUTICLS INC's gross profit margin for the first quarter of its fiscal year 2014 has decreased when compared to the same period a year ago. Even though sales increased, the net income has decreased, representing a decrease to the bottom line. PEREGRINE PHARMACEUTICLS INC is extremely liquid. Currently, the Quick Ratio is 3.53 which clearly shows the ability to cover any short-term cash needs. The company's liquidity has increased from the same period last year.
At the same time, stockholders' equity ("net worth") has greatly increased by 101.55% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is very unlikely to face financial difficulties in the near future.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.
|Income Statement||Q1 FY14||Q1 FY13|
|Net Sales ($mil)||5.5||4.69|
|Net Income ($mil)||-13.13||-7.6|
|Balance Sheet||Q1 FY14||Q1 FY13|
|Cash & Equiv. ($mil)||73.26||41.6|
|Total Assets ($mil)||87.61||53.32|
|Total Debt ($mil)||0.0||0.0|
|Profitability||Q1 FY14||Q1 FY13|
|Gross Profit Margin||39.85||48.53|
|Return on Assets||-46.67||-55.72|
|Return on Equity||-64.52||-91.31|
|Debt||Q1 FY14||Q1 FY13|
|Share Data||Q1 FY14||Q1 FY13|
|Shares outstanding (mil)||179.22||153.51|
|Div / share||0.0||0.0|
|Book value / share||0.37||0.21|
|Institutional Own %||n/a||n/a|
|Avg Daily Volume||1074628.0||1277047.0|
SELL. This stock?s P/E ratio is negative, making its value useless in the assessment of premium or discount valuation, only displaying that the company has negative earnings per share. Conducting a second comparison, its price-to-book ratio of 3.94 indicates a premium versus the S&P 500 average of 2.49 and a significant discount versus the industry average of 11.22. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, PEREGRINE PHARMACEUTICLS INC proves to trade at a discount to investment alternatives within the industry.
|PPHM NM||Peers 79.53||PPHM NM||Peers 37.89|
Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.
PPHM's P/E is negative making this valuation measure meaningless.
Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.
PPHM's P/CF is negative making the measure meaningless.
|PPHM NM||Peers 34.24||PPHM NA||Peers 1.17|
Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.
PPHM's ratio is negative making this valuation measure meaningless.
Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.
Ratio not available.
|PPHM 3.94||Peers 11.22||PPHM -8.69||Peers 12.05|
Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.
PPHM is trading at a significant discount to its peers.
Lower. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.
However, PPHM is expected to significantly trail its peers on the basis of its earnings growth rate.
|PPHM 11.12||Peers 102.50||PPHM 4.92||Peers 378.68|
Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.
PPHM is trading at a significant discount to its industry on this measurement.
Lower. A sales growth rate that trails the industry implies that a company is losing market share.
PPHM significantly trails its peers on the basis of sales growth
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV